Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 161,035,104
  • Shares Outstanding, K 5,686,268
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,118 M
  • EBITDA $ 25,710 M
  • 60-Month Beta 0.43
  • Price/Sales 2.59
  • Price/Cash Flow 6.49
  • Price/Book 1.87

Options Overview Details

View History
  • Implied Volatility 27.60% (+0.23%)
  • Historical Volatility 21.57%
  • IV Percentile 74%
  • IV Rank 27.57%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 7) 0.64 (2.25%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 96,800
  • Volume Avg (30-Day) 110,806
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 2,399,657
  • Open Int (30-Day) 2,577,043
  • Expected Range 27.68 to 28.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.77
  • Number of Estimates 7
  • High Estimate $0.92
  • Low Estimate $0.64
  • Prior Year $0.92
  • Growth Rate Est. (year over year) -16.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.20 +8.09%
on 03/05/26
28.75 -1.48%
on 04/02/26
+1.06 (+3.89%)
since 03/02/26
3-Month
24.95 +13.51%
on 01/05/26
28.75 -1.48%
on 04/02/26
+3.14 (+12.47%)
since 01/02/26
52-Week
20.92 +35.41%
on 04/09/25
28.75 -1.48%
on 04/02/26
+3.62 (+14.66%)
since 04/02/25

Most Recent Stories

More News
Trump unveils 100% tariff on some patented drugs on 'Liberation Day' anniversary

President Donald Trump has signed an executive order that could slap long-threatened pharmaceutical tariffs of up to 100% on some patented drugs from companies that don’t reach deals with his administration...

PFE : 28.32 (-0.81%)
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of...

PFE : 28.32 (-0.81%)
5 High-Yield Stocks to Shield Your Portfolio From the Storm

With the S&P 500 breaking below its 200-day SMA, high-yield dividend stocks are increasingly worth considering as a source of income and portfolio protection.

VZ : 49.40 (+0.02%)
BTI : 58.28 (+0.67%)
KHC : 22.79 (+2.33%)
MPLX : 55.90 (-0.04%)
SPY : 655.83 (+0.09%)
PFE : 28.32 (-0.81%)
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational...

VALN : 6.10 (-2.71%)
PFE : 28.32 (-0.81%)
2 Unpopular Stocks That Should Get More Attention and 1 We Avoid

2 Unpopular Stocks That Should Get More Attention and 1 We Avoid

TER : 309.61 (-0.83%)
BHF : 59.78 (+0.25%)
PFE : 28.32 (-0.81%)
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pfizer common stock at a price...

PFE : 28.32 (-0.81%)
Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their...

ADI : 318.34 (-0.70%)
MCHP : 65.60 (+0.34%)
IVZ : 24.14 (-0.74%)
PFE : 28.32 (-0.81%)
Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

XLV : 146.81 (-0.62%)
VHT : 273.07 (-0.52%)
$SRHC : 1,712.34 (-0.68%)
PFE : 28.32 (-0.81%)
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic hormone...

PFE : 28.32 (-0.81%)
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile ...

PFE : 28.32 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 29.16
2nd Resistance Point 28.95
1st Resistance Point 28.64
Last Price 28.32
1st Support Level 28.11
2nd Support Level 27.90
3rd Support Level 27.59

See More

52-Week High 28.75
Last Price 28.32
Fibonacci 61.8% 25.75
Fibonacci 50% 24.83
Fibonacci 38.2% 23.91
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.